Pfizer has inaugurated a newly built 6,000 square meter, €150 ($218) million biomanufacturing facility in Strangnas, Sweden, next to an existing plant previously owned by Pharmacia (acquired by New York–based Pfizer in 2003). When fully operational in 2011, the facility will make acromegaly treatment Somavert (pegvisomant) and recombinant DNA growth hormone Genotropin (somatropin), with the added flexibility to produce other biologics, possibly for contract. The new facility will be connected to the existing one, easing the flow of materials and personnel. “This is one of the largest investments in biomanufacturing in Scandinavia for a long time,” comments Ylva Hultman Erlandsson, life sciences business development manager at Stockholm Business Region Development. Erlandsson, who was instrumental in securing the facility for Sweden, adds that Puerto Rico, Singapore and Ireland were strong contenders for the new plant's location. “The most important reason for Pfizer's decision to locate here is that there has been bioproduction in Sweden for a long time and there are unique competences and experience in the Stockholm region.” Sweden has a strong track record in biologics manufacture—both Genotropin and Fragmin are of Swedish origin. Erlandsson also cites strong local and national support. “There was very good cooperation from everyone, including the Prime Minister and all the different agencies—all of whom really wanted Pfizer to establish this business in Sweden,” she says